Initial ICU Management of Skin Sloughing Diseases: Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome

  • T. L. Palmieri
Conference paper


Case Presentation: A 48 year old woman with metastatic breast cancer develops signs of an upper respiratory infection, fever, and malaise two weeks after starting dilantin for seizures from brain metastases. In the ensuing 48 hours, she develops skin eruptions on her face, which progress to her upper extremities and trunk. She develops lesions of the mouth as well as bullae over her trunk and extremities. She is admitted to the intensive care unit (ICU) hypotensive, tachycardic, and acidotic with sloughing of the skin of her head, trunk, both arms, and legs.


Toxic Epidermal Necrolysis Epidermolysis Bullosa Erythema Multiforme Total Body Surface Area Staphylococcal Scald Skin Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lyell A (1956) Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 68:355–361PubMedCrossRefGoogle Scholar
  2. 2.
    Becker DS. (1998) Toxic epidermal necrolysis. Lancet 351:1417–1420PubMedCrossRefGoogle Scholar
  3. 3.
    Chan HC, Stern RS, Arndt KA, et al (1990) The incidence of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 126:43–47PubMedCrossRefGoogle Scholar
  4. 4.
    French LE (2006) Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome: our current understanding. Allergol Int 55:9–16PubMedCrossRefGoogle Scholar
  5. 5.
    Roujeau JC (1994) The spectrum of Stevens-Johnson Syndrome and toxic epidermal necrolysis: A clinical classification. J Invest Dermatol 102:28S–30SPubMedCrossRefGoogle Scholar
  6. 6.
    Correla O, Chosidow O, Saiag P, et al (1993) Evolving patterns of drug-induced toxic epidermal necrolysis. Dermatology 186:32–37CrossRefGoogle Scholar
  7. 7.
    Heimbach DM, Engrav LH, Marvin JA, Harnar TJ, Grube BJ (1987) Toxic epidermal necrolysis: a step forward in the treatment. JAMA 257:2171–2175PubMedCrossRefGoogle Scholar
  8. 8.
    Kelemen JJ 3rd, Cioffi WC, McManus WF, Mason AD Jr, Pruitt B Jr (1995) Burn Center care for patients with toxic epidermal necrolysis. J Am Coll Surg 180:273–278PubMedGoogle Scholar
  9. 9.
    Zoltie N, Verlende P, O’Neill TJ, Mc Kenzie AW (1994) Lyell’s syndrome on a burns unit. Burns 20:368–370PubMedCrossRefGoogle Scholar
  10. 10.
    Palmieri TL, Greenhalgh DG, Saffle JR, et al (2002) A multicenter review of toxic epidermal necrolysis treated in U.S. Burn Centers at the end of the twentieth century. J Burn Care Rehabil 23:87–96PubMedCrossRefGoogle Scholar
  11. 11.
    Hermes B, Haas N, Henz BM (1996) Plasmapheresis and immunopathogenic aspects of toxic epidermal necrolysis. Hautarzt 47:749–753PubMedCrossRefGoogle Scholar
  12. 12.
    Breathnach SM McGibbon DH, Ive FA, Black MM (1982) Carbamazepine and toxic epidermal necrolysis: report of three cases with histopathological observations. Clin Exp Dermatol 7:585–591PubMedCrossRefGoogle Scholar
  13. 13.
    Peck GL, Elias PM, Graw RG Jr (1972) Graft-versus-host reaction and toxic epidermal necrolysis. Lancet 2:1151–1153PubMedCrossRefGoogle Scholar
  14. 14.
    Viard I, Wehrli P, Bullani R, et al (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490–493PubMedCrossRefGoogle Scholar
  15. 15.
    Rojeau JC, Kelly JP, Rzany B, et al (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333:1600–1607CrossRefGoogle Scholar
  16. 16.
    Guillaume JF, Roujeau JC, Revuz J, et al (1987) The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell syndrome). Arch Dermatol 123:1166–1170PubMedCrossRefGoogle Scholar
  17. 17.
    Halebian P, Corder V, Herndon D, Shires GT (1983) A burn center experience with toxic epidermal necrolysis. J Burn Care Rehabil 4:176–183CrossRefGoogle Scholar
  18. 18.
    Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG (2000) A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 21:199–204PubMedCrossRefGoogle Scholar
  19. 19.
    Wahle D, Beste D, Conley SF (1992) Laryngeal involvement in toxic epidermal necrolysis. Otolaryngol Head Neck Surg 6:796–799Google Scholar
  20. 20.
    Lebargy F, Wolkenstein P, Gisselbrecht M, et al (1997) Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 23:1237–1244PubMedCrossRefGoogle Scholar
  21. 21.
    Wilkins J, Morrison L, White CR (1990) Oculocutaneous manifestations of the erythema multiforme/Stevens-Johnson syndrome: descriptive and therapeutic controversy. Chest 98:331–336CrossRefGoogle Scholar
  22. 22.
    Marvin JA, Heimbach DM, Engrav LH, Harnar TJ (1984) Improved treatment of the Stevens-Johnson syndrome. Arch Surg 119:601–605PubMedGoogle Scholar
  23. 23.
    McGee T, Munster A (1998) Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to a regional burn center. Plast Reconstr Surg 102:1018–1022PubMedCrossRefGoogle Scholar
  24. 24.
    Bradley T, Brown RE, Kucan JO, Smoot EC, Hussmann J (1995) Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage. Ann Plast Surg 35:124–132PubMedCrossRefGoogle Scholar
  25. 25.
    Birchall N, Langdon R, Cuono C, McGuire J (1987) Toxic epidermal necrolysis: an approach to management using cryopreserved allograft skin. J Am Acad Dermatol 16:368–372PubMedCrossRefGoogle Scholar
  26. 26.
    Halebian PH, Madden MR, Finkestein JL, et al (1986) Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 204:503–511PubMedCrossRefGoogle Scholar
  27. 27.
    Engelhardt SL, Schurr MJ, Helgerson RB (1997) Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 18:520–524PubMedCrossRefGoogle Scholar
  28. 28.
    Prins C, Vittorio C, Padillar S, Hunzikar P et al (2003) Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson Syndrome: A retrospective, multicenter study. Dermatology 207:96–99PubMedCrossRefGoogle Scholar
  29. 29.
    Brown KM, Silver GM, Halerz M, et al (2004) Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 25:81–88PubMedCrossRefGoogle Scholar
  30. 30.
    Bachot N, Revuz J, Roujeau JC (2003) Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139:33–36PubMedCrossRefGoogle Scholar
  31. 31.
    Renfro L, Grant-Kels JM, Daman LA (1989) Drug-induced toxic epidermal necrolysis treated with cyclosporine. Int J Dermatol 28:441–444PubMedCrossRefGoogle Scholar
  32. 32.
    Egan C, Grant W, Morris S, Saffle J, Zone J (1999) Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 40:458–461PubMedCrossRefGoogle Scholar
  33. 33.
    Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149–153PubMedCrossRefGoogle Scholar
  34. 34.
    Trent JT, Kirsner RS, Romanelli P, Kerdel FA (2004) Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 140:890–892PubMedCrossRefGoogle Scholar
  35. 35.
    Spies M, Hollyoak M, Muller MJ, Goodwin CW, Herndon DN (2000) Exfoliative and necrotizing diseases of the skin. In: Herndon DN (ed) Total Burn Care, 2nd edn. W.B.Saunders, New York, pp 492–496Google Scholar

Copyright information

© Springer Science + Business Media Inc. 2008

Authors and Affiliations

  • T. L. Palmieri
    • 1
  1. 1.Dept of SurgeryUC Davis Regional Burn Center and Shriners Hospital for ChildrenSacramentoUSA

Personalised recommendations